Denali Therapeutics (DNLI) Short Interest Ratio & Short Volume → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free DNLI Stock Alerts $20.65 -0.12 (-0.58%) (As of 02:51 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Denali Therapeutics Short Interest DataCurrent Short Interest9,490,000 sharesPrevious Short Interest10,500,000 sharesChange Vs. Previous Month-9.62%Dollar Volume Sold Short$197.96 millionShort Interest Ratio8.0 Days to CoverLast Record DateMay 15, 2024Outstanding Shares142,610,000 sharesFloat Size117,260,000 sharesShort Percent of Float8.09%Today's Trading Volume520,227 sharesAverage Trading Volume1,136,825 sharesToday's Volume Vs. Average46% Short Selling Denali Therapeutics ? Sign up to receive the latest short interest report for Denali Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartDNLI Short Interest Over TimeDNLI Days to Cover Over TimeDNLI Percentage of Float Shorted Over Time Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. Denali Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20249,490,000 shares $197.96 million -9.6%8.1%8 $20.86 4/30/202410,500,000 shares $162.12 million +9.6%8.2%8.3 $15.44 4/15/20249,580,000 shares $170.91 million +1.8%8.3%7.9 $17.84 3/31/20249,410,000 shares $193.09 million +12.3%8.4%8 $20.52 3/15/20248,380,000 shares $168.69 million -5.5%7.5%7.2 $20.13 2/29/20248,870,000 shares $175.45 million -18.0%7.9%7.3 $19.78 Get the Latest News and Ratings for DNLI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/202410,820,000 shares $198.66 million +10.0%9.7%9.5 $18.36 1/31/20249,840,000 shares $157.54 million -0.4%9.0%9.4 $16.01 1/15/20249,880,000 shares $183.18 million +2.6%8.7%9.5 $18.54 12/31/20239,630,000 shares $206.66 million +5.4%8.5%9.7 $21.46 12/15/20239,140,000 shares $209.67 million +0.2%8.0%9.2 $22.94 11/30/20239,120,000 shares $168.90 million -4.6%8.0%10.1 $18.52 11/15/20239,560,000 shares $176.67 million -10.9%8.4%11.2 $18.48 10/31/202310,730,000 shares $202.05 million +12.7%9.5%13.9 $18.83 10/15/20239,520,000 shares $197.64 million -2.0%8.8%13.7 $20.76 9/30/20239,710,000 shares $200.32 million +3.6%8.9%15.1 $20.63 9/15/20239,370,000 shares $220.66 million +3.1%8.6%15.4 $23.55 8/31/20239,090,000 shares $209.89 million -1.5%8.3%14 $23.09 8/15/20239,230,000 shares $224.20 million +6.2%8.5%13.9 $24.29 7/31/20238,690,000 shares $247.06 million +6.4%8.1%12.6 $28.43 7/15/20238,170,000 shares $239.63 million +1.4%7.7%11.4 $29.33 6/30/20238,060,000 shares $237.85 million -7.7%7.5%10.5 $29.51 6/15/20238,730,000 shares $283.64 million +8.0%8.2%11.1 $32.49 5/31/20238,080,000 shares $244.18 million -6.4%7.6%10.8 $30.22 5/15/20238,630,000 shares $276.33 million No Change8.1%11.4 $32.02 10/31/20226,980,000 shares $200.19 million -4.3%6.2%8.4 $28.68 10/15/20227,290,000 shares $237.44 million +2.7%6.6%9 $32.57 9/30/20227,100,000 shares $217.90 million +6.6%7.0%10.5 $30.69 9/15/20226,660,000 shares $207.06 million +0.2%6.5%10.5 $31.09 8/31/20226,650,000 shares $184.01 million +2.0%6.5%9.9 $27.67 8/15/20226,520,000 shares $245.22 million -11.5%6.4%10.4 $37.61 7/31/20227,370,000 shares $250.73 million -2.5%7.6%11.2 $34.02 7/15/20227,560,000 shares $262.33 million -0.4%7.8%12 $34.70 6/30/20227,590,000 shares $223.37 million -3.2%7.8%12.5 $29.43 6/15/20227,840,000 shares $177.03 million +0.5%8.1%13.4 $22.58 5/31/20227,800,000 shares $189.46 million +5.4%8.0%14.7 $24.29 5/15/20227,400,000 shares $169.16 million +11.1%7.6%13.7 $22.86 4/30/20226,660,000 shares $158.51 million +1.1%6.9%12.8 $23.80 4/15/20226,590,000 shares $198.42 million -2.2%6.8%12.9 $30.11 3/31/20226,740,000 shares $216.83 million +0.2%N/A11.5 $32.17Chances are you know the firms on this list (Ad)These are the entities that can buy MILLIONS of shares in a single day… I’m talking about huge orders that literally move the share price 1%, 2%, even 5% or more in the process. Why am I showing you that list? Well, because if you have a way to successfully detect which stocks these elite traders are likely buying in real time… All you have to do is ride the coattails of their massive orders and you can target endless trading opportunities without leaving your money exposed to the markets for too long. And in case you didn’t already know…That’s exactly how this expert trader plans to trade his #1 ticker for 2024 3/15/20226,730,000 shares $199.28 million +3.5%6.9%11.5 $29.61 2/28/20226,500,000 shares $211.64 million -2.1%7.8%11.1 $32.56 2/15/20226,640,000 shares $236.65 million +20.7%8.0%11.3 $35.64 1/31/20225,500,000 shares $188.21 million +1.7%6.7%9.6 $34.22 1/15/20225,410,000 shares $188.48 million +2.3%6.6%10 $34.84 12/31/20215,290,000 shares $235.93 million -7.5%6.5%11.2 $44.60 12/15/20215,720,000 shares $260.32 million +9.8%7.0%11.7 $45.51 11/30/20215,210,000 shares $241.01 million -4.6%6.4%10.4 $46.26 11/15/20215,460,000 shares $273.66 million -3.4%6.7%11.3 $50.12 10/29/20215,650,000 shares $273.18 million -6.6%6.9%12.1 $48.35 10/15/20216,050,000 shares $275.64 million -6.2%7.4%12.8 $45.56 9/30/20216,450,000 shares $325.40 million +10.6%7.8%12.2 $50.45 9/15/20215,830,000 shares $306.83 million +1.0%7.1%9.9 $52.63 8/31/20215,770,000 shares $306.96 million +1.2%7.0%10.1 $53.20 8/13/20215,700,000 shares $300.56 million +3.8%6.9%8.8 $52.73 7/30/20215,490,000 shares $280.15 million +7.0%6.7%8.3 $51.03 7/15/20215,130,000 shares $329.45 million -6.9%6.1%7.9 $64.22 6/30/20215,510,000 shares $432.20 million +2.0%6.5%9 $78.44 6/15/20215,400,000 shares $397.33 million -5.4%6.4%10.2 $73.58 5/28/20215,710,000 shares $363.10 million -3.4%6.8%11.3 $63.59 5/14/20215,910,000 shares $305.55 million -4.1%7.1%11.1 $51.70 4/30/20216,160,000 shares $377.73 million -4.9%7.5%11.4 $61.32 4/15/20216,480,000 shares $358.21 million -1.7%N/A12 $55.28 3/31/20216,590,000 shares $357.24 million -1.2%8.1%11.7 $54.21 3/15/20216,670,000 shares $431.48 million -0.5%8.2%10.3 $64.69 2/26/20216,700,000 shares $422.10 million -3.9%8.3%9.8 $63.00 2/12/20216,970,000 shares $484.76 million -1.4%8.7%10.5 $69.55 1/29/20217,070,000 shares $500.98 million -4.2%9.3%10 $70.86 1/15/20217,380,000 shares $546.05 million -8.6%9.7%10 $73.99 12/31/20208,070,000 shares $691.20 million -6.2%10.7%11.1 $85.65 12/15/20208,600,000 shares $707.52 million +0.7%11.4%12.6 $82.27 11/30/20208,540,000 shares $523.25 million -5.1%11.3%12.5 $61.27 11/15/20209,000,000 shares $586.53 million -1.8%11.9%13.9 $65.17 10/30/20209,160,000 shares $417.33 million -4.7%12.5%14.5 $45.56 10/15/20209,610,000 shares $418.13 million +5.3%14.3%13.8 $43.51 9/30/20209,130,000 shares $327.13 million -1.2%12.5%13.2 $35.83 9/15/20209,240,000 shares $344.37 million +3.1%12.7%13.1 $37.27 8/31/20208,960,000 shares $285.82 million +1.7%12.3%12.6 $31.90 8/14/20208,810,000 shares $269.94 million -11.1%12.1%12.4 $30.64 7/31/20209,910,000 shares $232.09 million +0.6%13.6%15.4 $23.42 7/15/20209,850,000 shares $254.13 million -11.3%13.6%18.9 $25.80 6/30/202011,110,000 shares $263.31 million +14.3%15.3%22 $23.70 6/15/20209,720,000 shares $249.42 million +6.0%13.4%20.1 $25.66 5/29/20209,170,000 shares $255.20 million +2.3%12.7%18.7 $27.83 5/15/20208,960,000 shares $206.71 million -0.6%12.4%16.7 $23.07 4/30/20209,010,000 shares $209.30 million -1.7%12.5%16.8 $23.23 4/15/20209,170,000 shares $183.49 million +2.9%12.7%13.3 $20.01 3/31/20208,910,000 shares $202.88 million -5.9%12.4%11.8 $22.77 3/13/20209,469,800 shares $185.23 million -8.4%13.2%14.9 $19.56 2/28/202010,340,000 shares $173.20 million +0.9%14.4%16.2 $16.75Chances are you know the firms on this list (Ad)These are the entities that can buy MILLIONS of shares in a single day… I’m talking about huge orders that literally move the share price 1%, 2%, even 5% or more in the process. Why am I showing you that list? Well, because if you have a way to successfully detect which stocks these elite traders are likely buying in real time… All you have to do is ride the coattails of their massive orders and you can target endless trading opportunities without leaving your money exposed to the markets for too long. And in case you didn’t already know…That’s exactly how this expert trader plans to trade his #1 ticker for 2024 2/14/202010,250,000 shares $184.40 million -2.8%14.4%17.9 $17.99 1/31/202010,540,000 shares $227.98 million +6.7%15.4%19.2 $21.63 1/15/20209,880,000 shares $242.95 million +3.8%15.8%22.5 $24.59 12/31/20199,520,000 shares $234.67 million -3.0%15.2%26.6 $24.65 8/15/201910,628,000 shares $193.43 million -0.8%17.8%31.6 $18.20 DNLI Short Interest - Frequently Asked Questions What is Denali Therapeutics' current short interest? Short interest is the volume of Denali Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 9,490,000 shares of DNLI short. 8.09% of Denali Therapeutics' shares are currently sold short. Learn More on Denali Therapeutics' current short interest. What is a good short interest ratio for Denali Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DNLI shares currently have a short interest ratio of 8.0. Learn More on Denali Therapeutics's short interest ratio. Which institutional investors are shorting Denali Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Denali Therapeutics: PEAK6 Investments LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Denali Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.09% of Denali Therapeutics' floating shares are currently sold short. Is Denali Therapeutics' short interest increasing or decreasing? Denali Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 9,490,000 shares, a decline of 9.6% from the previous total of 10,500,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Denali Therapeutics' float size? Denali Therapeutics currently has issued a total of 142,610,000 shares. Some of Denali Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Denali Therapeutics currently has a public float of 117,260,000 shares. How does Denali Therapeutics' short interest compare to its competitors? 8.09% of Denali Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Denali Therapeutics: Prothena Co. plc (12.11%), REGENXBIO Inc. (8.14%), Cytokinetics, Incorporated (14.05%), Qiagen (1.39%), Repligen Co. (8.38%), Vaxcyte, Inc. (8.75%), Exelixis, Inc. (3.77%), Revolution Medicines, Inc. (7.84%), Halozyme Therapeutics, Inc. (6.80%), Krystal Biotech, Inc. (9.84%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Denali Therapeutics stock? Short selling DNLI is an investing strategy that aims to generate trading profit from Denali Therapeutics as its price is falling. DNLI shares are trading down $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Denali Therapeutics? A short squeeze for Denali Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of DNLI, which in turn drives the price of the stock up even further. How often is Denali Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DNLI, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Prothena Short Squeeze REGENXBIO Short Squeeze Cytokinetics Short Squeeze Qiagen Short Squeeze Repligen Short Squeeze Vaxcyte Short Squeeze Exelixis Short Squeeze Revolution Medicines Short Squeeze Halozyme Therapeutics Short Squeeze Krystal Biotech Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:DNLI) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored[PDF Inside] Crypto's $1 Trillion 60-Day Boom + New 2024 Profit StrategyThe crypto industry is exploding and Chris Munch just released a new PDF detailing how you can potentially pro...DeFi Distribution | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.